Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02635776 · ClinicalTrials.gov registry record · Phase 3
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
A Phase 3 study of Peanut Allergy, sponsored by Aimmune Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 555
- Enrollment target
- 20
- Study locations
NCT02635776 is a Phase 3 study of Peanut Allergy that has completed, run by Aimmune Therapeutics. The registered enrollment target is 555 participants, above the 172-participant average among 13 other Peanut Allergy trials with a reported enrollment target (223% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT02635776, a Phase 3 study of Peanut Allergy, has completed, sponsored by Aimmune Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 555 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut-allergic children and adults.
Conditions Studied
Interventions
- BIOLOGICAL AR101 powder provided in capsules & sachets
- BIOLOGICAL Placebo powder provided in capsules & sachets
Study Locations (20)
California
- Long Beach Memorial Medical Center / Miller Children's and Women's Hospital - Long Beach
- UCLA Medical Center, Santa Monica - Los Angeles
- Allergy & Asthma Associates of Southern California dba Southern California Research - Mission Viejo
- Sean N. Parker Center for Allergy Research, LPCH at El Camino Hospital - Mountain View
- Peninsula Research Associates, Inc. - Rolling Hills Estates
- Allergy & Asthma Medical Group and Research Center, A.P.C - San Diego
- Rady Children's Hospital - San Diego
- University of California, San Francisco - San Francisco
Colorado
- Children's Hospital Colorado - Aurora
- Colorado Allergy & Asthma Centers, P.C. - Centennial
- National Jewish Health - Denver
Florida
- Windom Allergy, Asthma and Sinus - Sarasota
- University of South Florida Asthma, Allergy & Immunology Clinical Research Unit - Tampa
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
- Comer Children's Hospital - Chicago
Arizona
- Banner University of Arizona Medical Center - Tucson
Arkansas
- Arkansas Children's Hospital - Little Rock
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Atlanta Allergy & Asthma Clinic, PA - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 555 participants |
| Start Date | 2015-12-22 |
| Est. Completion | 2018-07-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02635776
The ClinicalTrials.gov registry entry for NCT02635776 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 555 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 172-participant average among 13 other Peanut Allergy trials with a reported enrollment target (223% higher). The listed sponsor is Aimmune Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peanut Allergy appearing as the primary indexed condition, and to 2 interventions - of which AR101 powder provided in capsules & sachets is the first listed.
NCT02635776 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT02635776 about?
NCT02635776 is a clinical study titled "Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)". The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut-allergic children and adults.
What is the current status of trial NCT02635776?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 555 participants. The study started on 2015-12-22. Estimated completion is 2018-07-02.
What conditions does trial NCT02635776 study?
This clinical trial studies the following conditions: Peanut Allergy.
What interventions are being tested in trial NCT02635776?
The interventions under investigation include: AR101 powder provided in capsules & sachets (BIOLOGICAL), Placebo powder provided in capsules & sachets (BIOLOGICAL).
Who is sponsoring clinical trial NCT02635776?
This trial is sponsored by Aimmune Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02635776 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peanut Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
Safety Study of Viaskin Peanut to Treat Peanut Allergy
COMPLETED · Phase 3
-
AR101 Real-World Open-Label Extension Study
COMPLETED · Phase 3
-
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
COMPLETED · Phase 3
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.